Mounjaro
Online consultations with licensed providers
FDA-approved for adults with type 2 diabetes
The active ingredient is tirzepatide, which acts on GLP-1 and GIP
Eligibility required. A licensed provider must evaluate your medical history before any prescription is written.
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication approved by the FDA for adults with type 2 diabetes. It belongs to a newer class of drugs that acts on two separate gut hormones - GLP-1 and GIP - rather than just one, which is part of why it has drawn so much attention among both diabetes patients and people asking about weight management.
Tirzepatide is also sold under the brand name Zepbound, which carries a separate FDA approval specifically for chronic weight management. When Mounjaro is used for weight loss rather than diabetes, it is considered an off-label use - something a RoenRx provider can discuss with you directly during your visit, including whether Zepbound might be the more appropriate option for your goals.
Mounjaro is different from GLP-1-only medications like semaglutide because tirzepatide acts on two hormone pathways rather than one.
Tirzepatide mimics two hormones your body already produces after eating: GLP-1 and GIP. Together, they signal your pancreas to release more insulin when blood sugar rises, slow down how quickly food leaves your stomach, and turn down your appetite.
In people with type 2 diabetes, this combination helps bring blood sugar under control. A common side effect many patients notice is reduced hunger, which is why the drug has become closely linked to weight loss conversations even outside its approved use. Clinical trial data published in the New England Journal of Medicine found meaningful A1C reductions with tirzepatide compared to a leading GLP-1-only medication.
Eligibility is determined by a licensed healthcare provider, not by you or by us. Generally, candidates for Mounjaro:
If you are primarily interested in weight loss rather than diabetes management, your RoenRx provider may recommend evaluating you for Zepbound instead, since it is the version of tirzepatide specifically approved for that purpose.
Mounjaro's list price without insurance typically runs in the four-figure range per month, though many commercially insured patients pay significantly less, and Eli Lilly offers a savings card program for eligible patients. RoenRx's clinical visit fee is separate from the cost of the medication itself, which is billed by your pharmacy based on your specific insurance and formulary. Our team can help you understand what documentation your insurer may require for prior authorization. Compare Ozempic or learn about semaglutide.
Getting started with RoenRx takes just a few steps.
Tell us about your medical history, current medications, and health goals. It takes about 5 minutes.
A board-certified clinician reviews your intake and discusses whether Mounjaro, Zepbound, or another option fits your situation.
If your provider determines you are a good candidate, your prescription is sent directly to a pharmacy.
Your provider stays involved, monitoring progress, adjusting your plan, and answering questions as you go.
No. Mounjaro's active ingredient is tirzepatide, while Ozempic's is semaglutide. Both are injectable hormone-mimicking medications approved for type 2 diabetes, but they act on different receptors, and clinical studies have found some differences in average outcomes between the two.
Mounjaro's FDA approval is specifically for type 2 diabetes. If you are seeking treatment primarily for weight loss, your provider will likely discuss Zepbound, which shares the same active ingredient and is approved for that use.
Individual results vary, and your provider can walk you through realistic expectations for your specific health profile during your visit.
The most commonly reported side effects include nausea, diarrhea, decreased appetite, and injection-site reactions. Mounjaro carries a boxed warning for risk of thyroid C-cell tumors based on animal studies. Your provider will review your full medical history to screen for contraindications before prescribing.
Coverage varies by plan. Our team helps navigate prior authorization and can flag manufacturer savings programs you may qualify for.
Mounjaro is not for everyone. It carries a boxed warning regarding the risk of thyroid C-cell tumors observed in animal studies; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This page is for informational purposes and is not a substitute for a one-on-one evaluation with a licensed healthcare provider.
Ready to find out if Mounjaro is right for you?
Start Your Free Assessment